<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The randomized phase II OPUS (<z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi> and Cetuximab in First-Line Treatment of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">Metastatic Colorectal Cancer</z:e>) study showed that <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> KRAS mutation status was predictive for outcome in patients receiving cetuximab plus FOLFOX-4 (<z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>/<z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>/folinic acid) as first-line therapy for <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: The biomarker analysis was extended through the use of additional DNA samples extracted from stained tissue sections </plain></SENT>
<SENT sid="2" pm="."><plain>KRAS and BRAF <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> mutation status was determined for new (and for BRAF, existing) samples using a PCR technique </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical outcome was reassessed according to mutation status </plain></SENT>
<SENT sid="4" pm="."><plain>Overall survival data are presented </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Of 315 KRAS evaluable patient samples (93%), 179 tumors (57%) were KRAS <z:mp ids='MP_0002169'>wild type</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Eleven of 309 (4%) KRAS/BRAF evaluable <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (<z:hpo ids='HP_0000001'>all</z:hpo> KRAS <z:mp ids='MP_0002169'>wild type</z:mp>) carried BRAF mutations </plain></SENT>
<SENT sid="7" pm="."><plain>The addition of cetuximab to FOLFOX-4 significantly improved progression-free survival (hazard ratio 0.567, P = 0.0064) and response (odds ratio 2.551, P = 0.0027) in patients with KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>A favorable effect on survival was also observed </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: These results confirm the efficacy of cetuximab plus FOLFOX-4 in the first-line treatment of patients with KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> mCRC and confirm KRAS mutation status as an effective predictive biomarker </plain></SENT>
<SENT sid="10" pm="."><plain>The small number of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with BRAF mutations precluded the drawing of definitive conclusions concerning the predictive or prognostic utility of this biomarker </plain></SENT>
</text></document>